These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 30195240)

  • 1. Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer.
    Zhang Y; Lv H; Luo L; Xu Y; Pan Y; Wang Y; Lin H; Xiong J; Guo P; Zhang J; Li X; Ye F
    Eur J Med Chem; 2018 Sep; 157():1300-1325. PubMed ID: 30195240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold.
    Zhang H; Wang J; Zhao HY; Yang XY; Lei H; Xin M; Cao YX; Zhang SQ
    Bioorg Med Chem; 2018 Jul; 26(12):3619-3633. PubMed ID: 29853340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 4,6-pyrimidinediamine derivatives as novel dual EGFR/FGFR inhibitors aimed EGFR/FGFR1-positive NSCLC.
    Xie Z; Wu K; Wang Y; Pan Y; Chen B; Cheng D; Pan S; Guo T; Du X; Fang L; Wang X; Ye F
    Eur J Med Chem; 2020 Feb; 187():111943. PubMed ID: 31846829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC.
    Chen Y; Wu J; Wang A; Qi Z; Jiang T; Chen C; Zou F; Hu C; Wang W; Wu H; Hu Z; Wang W; Wang B; Wang L; Ren T; Zhang S; Liu Q; Liu J
    Eur J Med Chem; 2017 Oct; 139():674-697. PubMed ID: 28850922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR
    Li J; An B; Song X; Zhang Q; Chen C; Wei S; Fan R; Li X; Zou Y
    Eur J Med Chem; 2021 Feb; 212():113019. PubMed ID: 33429247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
    Hossam M; Lasheen DS; Ismail NSM; Esmat A; Mansour AM; Singab ANB; Abouzid KAM
    Eur J Med Chem; 2018 Jan; 144():330-348. PubMed ID: 29275232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
    Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
    Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a prominent dual-target DDR1/EGFR inhibitor aimed DDR1/EGFR-positive NSCLC.
    Wang X; Lu Y; Chen S; Zhu Z; Fu Y; Zhang J; He J; Huang L; Luo L; Guo W; Xu Z; Xie Z; Xu X; Zhang Y; Ye F; Ma S
    Bioorg Chem; 2024 Aug; 149():107500. PubMed ID: 38823310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational design and synthesis of 2,4-dichloro-6-methyl pyrimidine derivatives as potential selective EGFR
    Duan L; Chu C; Huang X; Yao H; Wen J; Chen R; Wang C; Tu Y; Lv Q; Pan Q; Xu S
    Arch Pharm (Weinheim); 2024 May; 357(5):e2300736. PubMed ID: 38381049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors.
    Xiao Q; Qu R; Gao D; Yan Q; Tong L; Zhang W; Ding J; Xie H; Li Y
    Bioorg Med Chem; 2016 Jun; 24(12):2673-80. PubMed ID: 27131639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The synthesis and bioactivity of pyrrolo[2,3-d]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations.
    Xia Z; Huang R; Zhou X; Chai Y; Chen H; Ma L; Yu Q; Li Y; Li W; He Y
    Eur J Med Chem; 2021 Nov; 224():113711. PubMed ID: 34315040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors.
    Zhang L; Yang Y; Zhou H; Zheng Q; Li Y; Zheng S; Zhao S; Chen D; Fan C
    Eur J Med Chem; 2015 Sep; 102():445-63. PubMed ID: 26310890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
    Chang S; Zhang L; Xu S; Luo J; Lu X; Zhang Z; Xu T; Liu Y; Tu Z; Xu Y; Ren X; Geng M; Ding J; Pei D; Ding K
    J Med Chem; 2012 Mar; 55(6):2711-23. PubMed ID: 22339342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
    Song Z; Huang S; Yu H; Jiang Y; Wang C; Meng Q; Shu X; Sun H; Liu K; Li Y; Ma X
    Eur J Med Chem; 2017 Jun; 133():329-339. PubMed ID: 28395219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
    Song Z; Ge Y; Wang C; Huang S; Shu X; Liu K; Zhou Y; Ma X
    J Med Chem; 2016 Jul; 59(14):6580-94. PubMed ID: 26882288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of highly potent and selective EGFR
    Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
    Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC.
    Zhou P; Chen G; Gao M; Wu J
    Bioorg Med Chem; 2018 Dec; 26(23-24):6135-6145. PubMed ID: 30442506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors.
    Ji X; Peng T; Zhang X; Li J; Yang W; Tong L; Qu R; Jiang H; Ding J; Xie H; Liu H
    Bioorg Med Chem; 2014 Apr; 22(7):2366-78. PubMed ID: 24565969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET probe detecting non-small cell lung cancer susceptible to epidermal growth factor receptor tyrosine kinase inhibitor therapy.
    Makino A; Miyazaki A; Tomoike A; Kimura H; Arimitsu K; Hirata M; Ohmomo Y; Nishii R; Okazawa H; Kiyono Y; Ono M; Saji H
    Bioorg Med Chem; 2018 May; 26(8):1609-1613. PubMed ID: 29478801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.